Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of GW685698X for the Treatment Of Perennial Allergic Rhinitis in Adolescents and Adults

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00116818
First received: June 30, 2005
Last updated: September 13, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2005
  Primary Completion Date: May 2005 (Final data collection date for primary outcome measure)
Publications:
Patel D, Ratner P, Clements D, Wu W, Faris M, Philpot E. Lack of effect on hypothalamic-pituitary-adrenal (HPA) axis function by once-daily fluticasone furoate* nasal spray (FFNS) 110 mcg in adolescents and adults with perennial allergic rhinitis (PAR).
Patel P, Ratner P, Clements D, Wu W, Philpot E. Twenty-four hour serum and urine cortisol data support hypothalamic-pituitary adrenocortical axis safety of once-daily fluticasone furoate*nasal spray 110mcg in adolescents and adults with perennial allerg

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):